Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Ludlow Faculty Research Building #201, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.
Pancreatobiliary Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Seoul, Korea.
Surg Endosc. 2017 Nov;31(11):4656-4664. doi: 10.1007/s00464-017-5529-6. Epub 2017 Apr 7.
This study aimed to identify that Yonsei criteria (YC) can be regarded as a preoperative clinical parameter to predict biological behavior of the left-sided pancreatic cancer.
Between June 2007 and December 2014, 135 patients who underwent minimally invasive (MIS) or open distal pancreatectomy for left-sided pancreatic cancer were enrolled in this study consecutively. Perioperative short-term and long-term oncologic outcomes were analyzed according to the YC retrospectively.
Fifty-four and 81 patients did and did not meet the YC, respectively. Short-term oncologic outcomes were favorable among those meeting the YC even after propensity score matching. Patients within the YC also had better disease-free and disease-specific overall survival (p < 0.05). In analysis for receiver operating characteristic curve, area under curve of CA19-9 was satisfactory only within YC group. Multivariate analysis for disease-free survival identified the YC as a strong independent prognostic factor (p < 0.05). In preoperative clinical setting, patients' survival was clearly different based on following clinical groups, such as within YC, beyond YC, and unresectable.
Preoperative CT-based determined YC can predict excellent short-term and long-term oncologic outcomes. YC might have a potential role as a preoperative clinical staging for left-sided pancreatic cancer. External validations of YC based on multicenter cohorts are mandatory to confirm this oncologic significance of YC.
本研究旨在确定延世标准(YC)可作为预测左侧胰腺癌生物学行为的术前临床参数。
2007 年 6 月至 2014 年 12 月,连续纳入 135 例行微创(MIS)或开腹胰体尾切除术治疗左侧胰腺癌的患者。回顾性根据 YC 分析围手术期短期和长期肿瘤学结果。
YC 符合和不符合患者分别为 54 例和 81 例。即使在进行倾向评分匹配后,符合 YC 的患者短期肿瘤学结果良好。符合 YC 的患者无病和疾病特异性总生存率也更好(p<0.05)。在接受者操作特征曲线分析中,仅在 YC 组中 CA19-9 的曲线下面积令人满意。无病生存的多因素分析确定 YC 为独立的预后因素(p<0.05)。在术前临床情况下,患者的生存根据以下临床组明显不同,如符合 YC、不符合 YC 和无法切除。
基于术前 CT 确定的 YC 可以预测良好的短期和长期肿瘤学结果。YC 可能作为左侧胰腺癌的术前临床分期具有潜在作用。基于多中心队列的 YC 的外部验证对于证实 YC 的肿瘤学意义是必要的。